Next Article in Journal
B- and T-/NK-Cell Lymphomas in the 2022 International Consensus Classification of Mature Lymphoid Neoplasms and Comparison with the WHO Fifth Edition
Next Article in Special Issue
CAR-T and Bispecific Antibodies: The New Standard for Relapsed and Refractory Multiple Myeloma, or Reserved for Late-Line Salvage Therapy?
Previous Article in Journal
Artificial Intelligence, Lymphoid Neoplasms, and Prediction of MYC, BCL2, and BCL6 Gene Expression Using a Pan-Cancer Panel in Diffuse Large B-Cell Lymphoma
Previous Article in Special Issue
Elderly Patients with Newly Diagnosed Multiple Myeloma: Continuous or Fixed Duration Treatment?
 
 
Opinion

Article Versions Notes

Hemato 2024, 5(2), 144-156; https://doi.org/10.3390/hemato5020012
Action Date Notes Link
article xml file uploaded 9 April 2024 08:32 CEST Original file -
article xml uploaded. 9 April 2024 08:32 CEST Update https://www.mdpi.com/2673-6357/5/2/12/xml
article pdf uploaded. 9 April 2024 08:32 CEST Version of Record https://www.mdpi.com/2673-6357/5/2/12/pdf
article html file updated 9 April 2024 08:34 CEST Original file https://www.mdpi.com/2673-6357/5/2/12/html
Back to TopTop